10 x '20 Progress-Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

被引:563
作者
Boucher, Helen W. [1 ,2 ]
Talbot, George H. [3 ]
Benjamin, Daniel K., Jr. [4 ,5 ]
Bradley, John [6 ,7 ]
Guidos, Robert J. [8 ]
Jones, Ronald N. [9 ,10 ]
Murray, Barbara E. [11 ]
Bonomo, Robert A. [12 ,13 ,14 ,15 ]
Gilbert, David [16 ,17 ]
机构
[1] Tufts Univ, Sch Med, Div Geog Med & Infect Dis, Boston, MA 02111 USA
[2] Tufts Med Ctr, Boston, MA USA
[3] Talbot Advisors, Anna Maria, FL USA
[4] Duke Univ, Sch Med, Durham, NC USA
[5] Duke Clin Res Inst, Durham, NC USA
[6] Childrens Hosp San Diego, Div Infect Dis, San Diego, CA USA
[7] Univ Calif San Diego, Dept Pediat, Div Infect Dis, San Diego, CA 92103 USA
[8] Infect Dis Soc Amer, Arlington, VA 22209 USA
[9] JMI Labs, North Liberty, IA USA
[10] Tufts Univ, Sch Med, Boston, MA 02111 USA
[11] Univ Texas Med Sch Houston, Div Infect Dis, Houston, TX USA
[12] Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, Res Serv, Cleveland, OH USA
[13] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA
[14] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA
[15] Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA
[16] Providence Portland Med Ctr, Div Infect Dis, Portland, OR USA
[17] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
关键词
antibacterial agents; antimicrobials; gram-negative bacilli; drug development; clinical trials; antibiotic pipeline; IN-VITRO ACTIVITY; SIDEROPHORE MONOSULFACTAM BAL30072; ACQUIRED BACTERIAL PNEUMONIA; PSEUDOMONAS-AERUGINOSA; CLINICAL-TRIALS; ANTIBACTERIAL AGENTS; BETA-LACTAMASES; NXL104; CEFTAZIDIME; RESISTANCE;
D O I
10.1093/cid/cit152
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infections caused by antibiotic-resistant bacteria, especially the "ESKAPE" pathogens, continue to increase in frequency and cause significant morbidity and mortality. New antimicrobial agents are greatly needed to treat infections caused by gram-negative bacilli (GNB) resistant to currently available agents. The Infectious Diseases Society of America (IDSA) continues to propose legislative, regulatory, and funding solutions to this continuing crisis. The current report updates the status of development and approval of systemic antibiotics in the United States as of early 2013. Only 2 new antibiotics have been approved since IDSA's 2009 pipeline status report, and the number of new antibiotics annually approved for marketing in the United States continues to decline. We identified 7 drugs in clinical development for treatment of infections caused by resistant GNB. None of these agents was included in our 2009 list of antibacterial compounds in phase 2 or later development, but unfortunately none addresses the entire spectrum of clinically relevant GNB resistance. Our survey demonstrates some progress in development of new antibacterial drugs that target infections caused by resistant GNB, but progress remains alarmingly elusive. IDSA stresses our conviction that the antibiotic pipeline problem can be solved by the collaboration of global leaders to develop creative incentives that will stimulate new antibacterial research and development. Our aim is the creation of a sustainable global antibacterial drug research and development enterprise with the power in the short term to develop 10 new, safe, and efficacious systemically administered antibiotics by 2020 as called for in IDSA's "10 x '20 Initiative."
引用
收藏
页码:1685 / 1694
页数:10
相关论文
共 71 条
[1]  
Anacor, GSK 052
[2]  
[Anonymous], 2010, WALL STREET J
[3]   Antibiotic-Resistant Bugs in the 21st Century -- A Clinical Super-Challenge. [J].
Arias, Cesar A. ;
Murray, Barbara E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (05) :439-443
[4]   Combating evolution with intelligent design: the neoglycoside ACHN-490 [J].
Armstrong, Eliana S. ;
Miller, George H. .
CURRENT OPINION IN MICROBIOLOGY, 2010, 13 (05) :565-573
[5]   Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Bradley, John S. ;
Edwards, John E., Jr. ;
Gilbert, David ;
Rice, Louis B. ;
Scheld, Michael ;
Spellberg, Brad ;
Bartlett, John .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12
[6]  
Brookings Institution, FAC ANT DRUG DEV 201
[7]   A FUNCTIONAL CLASSIFICATION SCHEME FOR BETA-LACTAMASES AND ITS CORRELATION WITH MOLECULAR-STRUCTURE [J].
BUSH, K ;
JACOBY, GA ;
MEDEIROS, AA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1211-1233
[8]   Updated Functional Classification of β-Lactamases [J].
Bush, Karen ;
Jacoby, George A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (03) :969-976
[9]   New antimicrobial agents on the horizon [J].
Bush, Karen ;
Pucci, Michael J. .
BIOCHEMICAL PHARMACOLOGY, 2011, 82 (11) :1528-1539
[10]   New β-lactam antibiotics and β-lactamase inhibitors [J].
Bush, Karen ;
Macielag, Mark J. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (10) :1277-1293